Literature DB >> 23839227

Platinum compounds and sodium metabolism in children with diencephalic glioma.

N Puma1, A Ruggiero, M Scalzone, P Coccia, S Triarico, G Trombatore, S Mastrangelo, R Riccardi.   

Abstract

In this brief report we have described eight children affected by optic pathway/hypothalamus gliomas and treated with carboplatin and/or cisplatin, which developed a derangement of sodium and water metabolism, due to diabetes insipidus (DI) or to syndrome of inappropriate antidiuretic hormone secretion (SIADH) after surgical resection. In four out of these eight patients the treatment with platinum compounds produced prolonged haematological toxicity and in five out of them it caused neurosensorial bilateral hypoacusia. In addition cisplatin worsened electrolytes disturbances. Hence children with DI or SIADH should be carefully monitored before, during and after the treatment with platinum compounds.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23839227     DOI: 10.1007/s11060-013-1203-6

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  19 in total

Review 1.  Renal late effects in patients treated for cancer in childhood: a report from the Children's Oncology Group.

Authors:  Deborah P Jones; Sheri L Spunt; Daniel Green; James E Springate
Journal:  Pediatr Blood Cancer       Date:  2008-12       Impact factor: 3.167

Review 2.  Clinical development of platinum complexes in cancer therapy: an historical perspective and an update.

Authors:  D Lebwohl; R Canetta
Journal:  Eur J Cancer       Date:  1998-09       Impact factor: 9.162

3.  Cisplatin decreases the abundance of aquaporin water channels in rat kidney.

Authors:  Soo-Wan Kim; Jong-Un Lee; Myong-Yun Nah; Dae-Gill Kang; Kyu-Youn Ahn; Ho-Sub Lee; Ki-Chul Choi
Journal:  J Am Soc Nephrol       Date:  2001-05       Impact factor: 10.121

4.  Carboplatin and vincristine chemotherapy for children with newly diagnosed progressive low-grade gliomas.

Authors:  R J Packer; J Ater; J Allen; P Phillips; R Geyer; H S Nicholson; R Jakacki; E Kurczynski; M Needle; J Finlay; G Reaman; J M Boyett
Journal:  J Neurosurg       Date:  1997-05       Impact factor: 5.115

Review 5.  Optic pathway gliomas: a review.

Authors:  Mandy J Binning; James K Liu; John R W Kestle; Douglas L Brockmeyer; Marion L Walker
Journal:  Neurosurg Focus       Date:  2007       Impact factor: 4.047

6.  Intensive cisplatin and cyclophosphamide-based chemotherapy without radiotherapy for intracranial germinomas: failure of a primary chemotherapy approach.

Authors:  Stewart J Kellie; Hayden Boyce; Ira J Dunkel; Blanca Diez; Marc Rosenblum; Lynette Brualdi; Jonathan L Finlay
Journal:  Pediatr Blood Cancer       Date:  2004-08       Impact factor: 3.167

7.  Genetic variants in TPMT and COMT are associated with hearing loss in children receiving cisplatin chemotherapy.

Authors:  Colin J D Ross; Hagit Katzov-Eckert; Marie-Pierre Dubé; Beth Brooks; S Rod Rassekh; Amina Barhdadi; Yassamin Feroz-Zada; Henk Visscher; Andrew M K Brown; Michael J Rieder; Paul C Rogers; Michael S Phillips; Bruce C Carleton; Michael R Hayden
Journal:  Nat Genet       Date:  2009-11-08       Impact factor: 38.330

8.  Persistent nephrotoxicity during 10-year follow-up after cisplatin or carboplatin treatment in childhood: relevance of age and dose as risk factors.

Authors:  Roderick Skinner; Annie Parry; Lisa Price; Michael Cole; Alan W Craft; Andrew D J Pearson
Journal:  Eur J Cancer       Date:  2009-10-21       Impact factor: 9.162

9.  Challenges in management of patients with intracranial germ cell tumor and diabetes insipidus treated with cisplatin and/or ifosfamide based chemotherapy.

Authors:  Samina Afzal; Diane Wherrett; Ute Bartels; Uri Tabori; Annie Huang; Derek Stephens; Eric Bouffet
Journal:  J Neurooncol       Date:  2009-10-10       Impact factor: 4.130

Review 10.  Syndrome of inappropriate antidiuresis.

Authors:  L Kovacs; G L Robertson
Journal:  Endocrinol Metab Clin North Am       Date:  1992-12       Impact factor: 4.741

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.